Bristol-Myers Squibb Company (BMY)
$
48.28
+0.43 (0.89%)
Key metrics
Financial statements
Free cash flow per share
6.4431
Market cap
95.6 Billion
Price to sales ratio
2.0066
Debt to equity
2.9466
Current ratio
1.2789
Income quality
2.6339
Average inventory
2.6 Billion
ROE
0.3193
Technology
Technology – consumer electronics
Largecap
With a market cap of 121,78 bil stock is ranked 1
Low risk
ISS score of this stock is ranked 1
Company description
Profile
Bristol-Myers Squibb Company is engaged in the discovery, development, licensing, manufacturing, and marketing of biopharmaceutical products on a global scale, focusing on multiple therapeutic areas including hematology, oncology, cardiovascular diseases, immunology, fibrotic conditions, neuroscience, and COVID-19. The company's diverse portfolio features Revlimid, an oral immunomodulatory agent for treating multiple myeloma; Eliquis, an oral anticoagulant reducing the risk of stroke and systemic embolism in non-valvular atrial fibrillation (NVAF) while also treating DVT and PE; and Opdivo, which is utilized for various anti-cancer indications. Other prominent products include Pomalyst/Imnovid for multiple myeloma patients, Orencia for adults with active rheumatoid arthritis and psoriatic arthritis, and Sprycel for Philadelphia chromosome-positive chronic myeloid leukemia. Additionally, Yervoy addresses unresectable or metastatic melanoma, while Abraxane serves as a protein-bound chemotherapy option. Reblozyl treats anemia in adults with beta thalassemia, and Empliciti is indicated for multiple myeloma treatment. The company further extends its offerings with Zeposia for relapsing forms of multiple sclerosis, Breyanzi as a CD19-directed autologous T cell therapy for relapsed or refractory large B-cell lymphoma in adults, Inrebic, an oral kinase inhibitor for myelofibrosis, and Onureg for acute myeloid leukemia in adults. It distributes its products through wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government entities. The company recorded an operating income of $5,887,000,000.00 reflecting its earnings from core operations, with a cost of revenue amounting to $13,968,000,000.00 showcasing its production and operational expenses. The income before tax ratio is -0.17 depicting the pre-tax margin, while a significant net income of -$8,948,000,000.00 illustrates the company’s strong financial health. Additionally, the net income ratio stands at -0.19 reflecting the company's profitability margin. In the realm of market positioning, the stock is reasonably priced at $47.85 appealing to a broad range of investors. It has a high average trading volume of 14,850,865.00 indicating strong liquidity and a robust trading interest among stakeholders. With a large market capitalization of $98,253,662,400.00 the company emerges as a dominant player within the biopharmaceutical sector. It is a key player in the Drug Manufacturers - General industry, contributing significantly to the overall market landscape. Moreover, it belongs to the Healthcare sector, consistently driving innovation and growth in its field.
Is Bristol-Myers Squibb Company (BMY) a good investment?
Investing in Bristol-Myers Squibb Company (BMY) depends on multiple factors, including revenue growth, profit margins, debt-to-equity ratio, earnings per share, and return on equity. Analysts have rated it as B+, with a Bullish outlook. Always conduct your own research before investing.
What is Bristol-Myers Squibb Company (BMY)'s stock forecast?
Analysts predict Bristol-Myers Squibb Company stock to fluctuate between $39.35 (low) and $63.33 (high) in the next 365 days, reflecting market expectations and potential volatility.
What is Bristol-Myers Squibb Company's market capitalization?
As of 2025-05-30, Bristol-Myers Squibb Company's market cap is $98,253,662,400, based on 2,035,080,000 outstanding shares.
How does Bristol-Myers Squibb Company compare to competitors like Eli Lilly & Co.?
Compared to Eli Lilly & Co., Bristol-Myers Squibb Company has a Lower Market-Cap, indicating a difference in performance.
Does Bristol-Myers Squibb Company pay dividends?
Bristol-Myers Squibb Company pays dividends. The current dividend yield is 4.41%, with a payout of $0.62 per share.
How can I buy Bristol-Myers Squibb Company (BMY) stock?
To buy Bristol-Myers Squibb Company (BMY) stock: Open a brokerage account (e.g., Robinhood, TD Ameritrade, E-Trade). Search for BMY. Place an order (Market, Limit, etc.).
What is the best time to invest in Bristol-Myers Squibb Company?
The best time to invest depends on market trends and technical indicators, which show a Bullish trend based on economic conditions and company performance.
Has Bristol-Myers Squibb Company stock ever split?
Bristol-Myers Squibb Company's last stock split was 1000000:951777 on 2001-08-07.
How did Bristol-Myers Squibb Company perform in the last earnings report?
Revenue: $48,300,000,000 | EPS: -$4.41 | Growth: -213.66%.
Where can I find Bristol-Myers Squibb Company's investor relations reports?
Visit https://www.bms.com/investor-relations for detailed financial reports.
Where can I find historical stock prices for Bristol-Myers Squibb Company?
You can explore historical data from here
What is the all-time high and low for Bristol-Myers Squibb Company stock?
All-time high: $81.44 (2022-12-01) | All-time low: $39.35 (2024-07-05).
What are the key trends affecting Bristol-Myers Squibb Company stock?
Key trends include market demand, economic conditions, interest rates, and industry competition, which influence the stock's performance.
News
zacks.com
Bristol Myers' Opdivo SC wins EU approval as the first PD-1 inhibitor for subcutaneous use across multiple solid tumor indications.
seekingalpha.com
Bristol-Myers Squibb Company (NYSE:BMY ) Bernstein 41st Annual Strategic Decisions Conference May 28, 2025 3:30 PM ET Company Participants Chris Boerner - Chief Executive Officer & Chairman Conference Call Participants Courtney Breen - Bernstein Courtney Breen Fantastic. Hi, everyone.
seekingalpha.com
Bristol-Myers Squibb Company appears deeply undervalued, despite business headwinds and revenue declines from legacy products facing generic competition. The market is already pricing in revenue and EPS declines, but current valuation multiples—like a forward P/E below 7x—are excessively discounted. Even with conservative assumptions of 5% annual revenue decline and no terminal growth, fair value estimates show over 20% upside potential.
seekingalpha.com
I reiterate my buy rating on Bristol-Myers, seeing significant undervaluation despite persistent weak technicals and sector underperformance. BMY's strong earnings beats, high free cash flow yield, and nearly 6% dividend make it a compelling income play, even amid pipeline concerns. Valuation is attractive: a sub-7x forward P/E and high dividend yield more than discount muted growth and generic competition risks.
seekingalpha.com
Despite socio-economic challenges and pressure from the generic versions of Revlimid and Abraxane, Bristol-Myers Squibb Company's financial position continues to improve. It raised its 2025 diluted EPS guidance from $6.55-$6.85 to $6.7-$7, as well as revenue expectations from $45.5 billion to $45.8-$46.8 billion. Bristol-Myers Squibb's key franchises remain oncology and cardiovascular, primarily due to the strong performance of Opdivo, Camzyos, and Reblozyl.
seekingalpha.com
Focus on high-quality, dividend-paying stocks with temporary setbacks, offering both value and income for patient investors. Bristol-Myers Squibb is deeply undervalued, carries a 5.3% yield, strong profitability, and a promising neurodegenerative drug pipeline. Rexford Industrial Realty offers a 5% yield, benefits from supply-constrained Southern California industrial markets, and trades far below historical valuation.
zacks.com
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
businesswire.com
PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #ASCO--BMS to Present Data at ASCO® 2025 Highlighting Differentiated Research Platform of Oncology Treatments and Innovative Research Pipeline.
zacks.com
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
reuters.com
Bristol Myers Squibb will spend $40 billion in the US over the next five years, CEO Christopher Boerner wrote in an opinion piece published by Stat News on Monday.
See all news
